SCHEMBL427012

SCHEMBL427012

Cc1ccnc(NCCCN2CCOCC2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
EGFR P00533 2/20 0.54
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
CYP3A4 P08684 4/20 0.49
CYP1A2 P05177 3/20 0.49
CYP2D6 P10635 3/20 0.49
TSHR P16473 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
HSD17B10 Q99714 2/20 0.49
CYP2C19 P33261 2/20 0.49
HIF1A Q16665 1/20 0.49
KDM4E B2RXH2 3/20 0.48
POLB P06746 3/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
LMNA P02545 2/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9906945 0.92 CYP1A2 (0.57) ALDH1A1EGFRABL1BCRCYP3A4
SCHEMBL2831921 0.84 ABL1 (0.49) ALDH1A1EGFRABL1BCRCYP3A4
SCHEMBL11988642 0.84 FGFR1 (0.49) ALDH1A1EGFRABL1BCRCYP3A4
SCHEMBL12015770 0.84 ABL1 (0.47) ALDH1A1EGFRABL1BCRCYP3A4
SCHEMBL446124 0.82 CYP3A4 (0.51) ALDH1A1EGFRABL1BCRCYP3A4
SCHEMBL1654886 0.82 EGLN2 (0.53) ALDH1A1ABL1BCRCYP3A4CYP1A2
SCHEMBL13698127 0.82 ALDH1A1 (0.58) ALDH1A1EGFRCYP3A4CYP1A2CYP2D6
SCHEMBL11988213 0.80 DRD2 (0.57) ALDH1A1CYP3A4CYP1A2CYP2D6TSHR
SCHEMBL17896869 0.79 MAP4K4 (0.54) ALDH1A1KDM4EPOLBKMT2AMEN1
SCHEMBL13702362 0.78 CYP2C9 (0.53) ALDH1A1CYP2D6TSHRCYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642624-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2014-02-04 US disclosed
US-8642624-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2014-02-04 US disclosed
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-03-15 US disclosed
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-03-15 US disclosed
US-7687643-B2 Process for preparing 3,3-dimethylindolines AMGEN INC. (US) 2010-03-30 US disclosed
US-7687643-B2 Process for preparing 3,3-dimethylindolines AMGEN INC. (US) 2010-03-30 US disclosed
US-20090029991-A1 BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS ASTRAZENECA AB (SE) 2009-01-29 US disclosed
US-20090029991-A1 BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS ASTRAZENECA AB (SE) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029991-A1 BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC3, HDAC2 ALDH1A1 642/4885EGFR 3652/4885ABL1 2621/4885
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AADAC, NAT1, PIGO ALDH1A1 327/4885EGFR 572/4885ABL1 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.